Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Multiple Sclerosis, An Issue of Neurologic Clinics
- 1st Edition, Volume 42-1 - November 21, 2023
- Editor: Carrie M. Hersh
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 3 9 1 7 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 3 9 1 8 - 8
In this issue of Neurologic Clinics, guest editor Dr. Carrie M. Hersh brings her considerable expertise to the topic of Multiple Sclerosis. Top experts in the field discuss diagn… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Neurologic Clinics, guest editor Dr. Carrie M. Hersh brings her considerable expertise to the topic of Multiple Sclerosis. Top experts in the field discuss diagnosis and pathophysiology concepts, treatment, special populations in MS, and contemporary issues related to MS.
- Contains 16 relevant, practice-oriented topics including recent advances in diagnostic, prognostic, and disease monitoring biomarkers in MS; the growing problem of MS misdiagnosis; highly effective therapy versus escalation approaches in early MS; clinical considerations in the diagnosis, management, and treatment of MS in Black and Latinx populations; women’s health and pregnancy in MS; the era of COVID-19 in MS care; and more.
- Provides in-depth clinical reviews on multiple sclerosis, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Neurology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- Multiple Sclerosis Diagnostic Delay and Misdiagnosis
- Key points
- Introduction
- Delayed diagnosis of multiple sclerosis
- Misdiagnosis of multiple sclerosis
- Preventing diagnostic delay and multiple sclerosis misdiagnosis now and in the future
- Summary
- Clinics care points
- Disclosure
- Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis
- Key points
- Introduction
- Current diagnostic biomarkers for multiple sclerosis
- Emerging diagnostic biomarkers for multiple sclerosis
- Current prognostic biomarkers for multiple sclerosis
- Emerging prognostic biomarkers for multiple sclerosis
- Current disease-monitoring/treatment-response biomarkers
- Emerging disease-monitoring/treatment-response biomarkers
- Summary
- Author contributions
- Clinics care points
- Disclosures
- Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis: The Age of PIRA
- Key points
- Introduction
- Pathophysiology
- Diagnosis and Treatment
- Emerging therapeutic targets
- Discussion
- Summary
- Clinics care points
- Disclosure
- Relationship Between Multiple Sclerosis, Gut Dysbiosis, and Inflammation: Considerations for Treatment
- Key points
- Introduction
- Characterization of gut dysbiosis in people with multiple sclerosis
- Evidence for the relevance of gut dysbiosis from mouse models of multiple sclerosis
- Mechanism through which gut dysbiosis contributes to disease pathology
- Targeting the gut microbiome for treatment
- Supplementation of gut-derived metabolites
- Summary
- Clinics care points
- Disclosure
- Funding
- Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders
- Key points
- Introduction
- AQP4+NMOSD and MOGAD diagnosis
- Remission MRI
- AQP4+NMOSD and MOGAD treatment
- Summary
- Clinics care points
- Disclosure
- Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies
- Key points
- Introduction
- Treatment of multiple sclerosis acute exacerbations
- Treatment of relapsing multiple sclerosis
- B-cell–depleting therapies
- Natalizumab
- Alemtuzumab
- Fumarates
- Teriflunomide
- Sphingosine 1-phosphate receptor modulators
- Cladribine
- Interferon beta-1
- Glatiramer acetate
- Novel treatments under development
- Remyelination
- Multiple sclerosis risk mitigation
- Summary
- Clinics care points
- Disclosures/ Funding
- Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion
- Key points
- Introduction
- Part 1. Anti-CD20 monoclonal antibodies in relapsing multiple sclerosis—efficacy and mechanisms of action
- Part 2. B cell depletion using anti-CD20 monoclonal antibodies in progressive multiple sclerosis
- Part 3. Safety and long-term risks of peripheral B cell depletion in multiple sclerosis
- Summary
- Clinics care points
- Disclosure
- Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier
- Key points
- Introduction
- Discussion
- Summary
- Disclosure
- Clinics care points
- Autologous Hematopoietic Stem Cell Transplantation to Treat Multiple Sclerosis
- Key points
- Introduction
- Overview of autologous hematopoietic stem cell transplantation procedure
- Summary of efficacy results in previous studies
- Safety and tolerability
- Immunologic effects
- Current status and target population
- Unanswered questions
- Discussion
- Clinics care points
- Disclosure
- Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis: What Is the Future of Multiple Sclerosis Treatment?
- Key points
- Introduction
- Disease-modifying therapy profiles
- The escalation approach
- The early highly effective treatment approach
- Comparing Escalation and Early Highly Effective Treatment
- Future directions
- Summary
- Clinics care points
- Disclosure
- Leveraging Real-World Evidence and Observational Studies in Treating Multiple Sclerosis
- Key points
- Introduction
- Benefits and challenges of randomized controlled trials
- Benefits and challenges of real-world observational studies
- Methods for improving real-world observational studies
- Continued challenges and opportunities for improving real-world evidence generation
- Harnessing insights from real-world evidence: recent observational studies in multiple sclerosis
- Discussion and future perspectives
- Summary
- Clinics care points
- Disclosures
- Health, Wellness, and the Effect of Comorbidities on the Multiple Sclerosis Disease Course: Tackling the Modifiable
- Key points
- Introduction
- Mental health comorbidities
- Physical comorbidities
- Summary
- Disclosure
- Clinics care points
- Clinical and Treatment Considerations for the Pediatric and Aging Patients with Multiple Sclerosis
- Key points
- Introduction
- Clinical diagnosis and disease phenotypes across the lifespan
- Treatment and management considerations
- Summary
- Clinic care points
- Disclosure
- Women’s Health and Pregnancy in Multiple Sclerosis
- Key points
- Introduction
- Women’s health
- Specific disease-modifying therapies
- Relapses during pregnancy
- Healthy aging
- Summary
- Clinics care points
- Disclosures
- Multiple Sclerosis in Black and Hispanic Populations: Serving the Underserved
- Key points
- Introduction
- Prevalence, incidence, and mortality
- Comorbidities with multiple sclerosis
- Summary
- Clinics care points
- Disclosure
- Era of COVID-19 in Multiple Sclerosis Care
- Key points
- Introduction
- Disruptions along the continuum of multiple sclerosis care due to COVID-19
- Bringing care to people with multiple sclerosis using telemedicine
- The power of large registries for assessing COVID-19 risk in people with multiple sclerosis
- Symptomatic manifestations of COVID-19 in people with multiple sclerosis
- Impact of COVID-19 on disease-modifying therapy selection
- Vaccination against SARS-CoV-2 for people with multiple sclerosis
- Discussion
- Summary
- Clinics care points
- Disclosures
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 42-1
- Published: November 21, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780323939171
- eBook ISBN: 9780323939188
CH
Carrie M. Hersh
Affiliations and expertise
Program Director | Multiple Sclerosis Health and Wellness Initiative, Mellen Program for Multiple Sclerosis Treatment and Research, Lou Ruvo Center for Brain Health | Las Vegas